Impact of Surgical Removal or Reduction Procedures on Markers of Immune Function in Adult Patients with Renal and Bladder Tumors and Pediatric Patients with Genitourinary Tumors


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 16-006956
    Sponsor Protocol Number: 16-006956

About this study

The purpose of this study is to find out more about certain markers of immune suppression in people with kidney tumors (whether the tumors are benign or cancer). Also want to find out if kidney tumor treatment leads to an improvement in these immune markers.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria  

Subjects ≥ 18 years of age:

  • Age 18+ years
  • Able to give informed consent
  • Undergoing elective treatment for a solid renal/bladder tumor:
    • Partial nephrectomy/cystectomy
    • Radical nephrectomy/cystectomy
    • Nephrectomy + tumor thrombectomy
    • Cytoreductive nephrectomy +/- metastasectomy for metastatic RCC
    • Radiofrequency ablation or cryotherapy
    • Transurethral resection
    • Metastasectomy for mUC

Subjects < 18 years of age:

  • Age 0-17 years
  • Parent/Guardian able to give informed consent, and subject able to give assent (ages 7-17)
  • Undergoing elective treatment for genitourinary mass, and/or metastases from primary genitourinary tumor, and/or recurrence of genitourinary malignancy, any location, with tissue being obtained via:
    • Nephrectomy
    • Partial nephrectomy
    • Open biopsy
    • Percutaneous biopsy
    • Resection of mass

Exclusion Criteria

Subjects ≥ 18 years of age:

  • Bilateral tumors
  • Salvage procedure (i.e. treatment for a recurrent tumor)
  • Immunosuppressed patient (Use of immunosuppressive medications in past 90 days (Examples include: oral or IV corticosteroids (topical creams or nasal sprays are OK), anti-metabolites (ex. azathioprine, methotrexate), biologics (ex. infliximab), chemotherapy) or imunosuppressive condition (ex. transplant, immunodeficiency syndromes, HIV/AIDS)
  • Auto-immune disease (ex. lupus, rheumatoid arthritis, inflammatory bowel disease, etc.)
  • Pregnancy

Subjects < 18 years of age:

  • Metastases to kidney from non-renal primary
  • Auto-immune disease (ex. lupus, rheumatoid arthritis, inflammatory bowel disease, etc.)
  • Pregnancy


Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Leibovich, M.D.

Closed for enrollment

Contact information:

Leanne Sandieson


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions